Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2023-11-15 00:00:00 ET · period of report 2023-11-13 · accession 0001453687-23-000088 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-11-15 | 2023-11-13 | RNAC | Brunn Carsten | Pres, CEO, Dir | D - Sale to Iss | $2.06 | -521.1K | 544.8K | -49% | -$1.07M |
| DM | 2023-11-15 | 2023-11-13 | RNAC | Brunn Carsten | Pres, CEO, Dir | D - Sale to Iss | $0.7819 | -5.57M | 0 | -100% | -$4.35M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-13 | D | D | 13,600 | $2.06 | 714,481 | D | — | — | (F2) This unvested restricted stock, which was granted on September 24, 2021, was canceled in the Merger, in exchange for $28,016, representing $2.06 per share, the Cash-out Amount as applied in the Merger. |
| 2 | Common | Common Stock | 2023-11-13 | D | D | 55,000 | $2.06 | 728,081 | D | — | — | (F1) This unvested restricted stock, which was granted on January 4, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for $113,300, representing $2.06 per share, the Cash-out Amount as applied in the Merger. |
| 3 | Common | Common Stock | 2023-11-13 | D | D | 282,800 | $2.06 | 261,956 | D | — | — | (F4) This unvested restricted stock, which was granted on January 2, 2023, was canceled in the Merger, in exchange for $582,568, representing $2.06 per share, the Cash-out Amount as applied in the Merger. |
| 4 | Common | Common Stock | 2023-11-13 | D | D | 169,725 | $2.06 | 544,756 | D | — | — | (F3) This unvested restricted stock, which was granted on January 3, 2022, was canceled in the Merger, in exchange for $349,633.50, representing $2.06 per share, the Cash-out Amount as applied in the Merger. |
| 5 | Derivative | Employee Stock Option (right to buy) | 2023-11-13 | D | D | 330,000 | — | 0 | D | $2.20 · — to 2029-02-24 | 330,000 Common Stock | (F6) This option, which provided for vesting as to 25% of the shares on February 25, 2020 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. |
| 6 | Derivative | Employee Stock Option (right to buy) | 2023-11-13 | D | D | 400,000 | $0.31 | 0 | D | $1.75 · — to 2029-10-06 | 400,000 Common Stock | (F7) This option, which provided for vesting as to 50% of the shares on October 7, 2020 and the remaining 50% of the shares on October 7, 2021, was canceled in the Merger, in exchange for a cash payment of $124,000, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. |
| 7 | Derivative | Employee Stock Option (right to buy) | 2023-11-13 | D | D | 600,000 | — | 0 | D | $2.30 · — to 2030-01-01 | 600,000 Common Stock | (F8) This option, which provided for vesting as to 25% of the shares on January 2, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2023-11-13 | D | D | 670,000 | — | 0 | D | $2.99 · — to 2031-01-03 | 670,000 Common Stock | (F10) This option, which provided for vesting as to 25% of the shares on January 4, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2023-11-13 | D | D | 163,000 | — | 0 | D | $4.32 · — to 2031-09-23 | 163,000 Common Stock | (F11) This option, which provided for vesting as to 25% of the shares on September 24, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. |
| 10 | Derivative | Employee Stock Option (right to buy) | 2023-11-13 | D | D | 1,056,100 | — | 0 | D | $3.31 · — to 2032-01-02 | 1,056,100 Common Stock | (F12) This option, which provided for vesting as to 25% of the shares on January 3, 2023 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. |
| 11 | Derivative | Employee Stock Option (right to buy) | 2023-11-13 | D | D | 1,275,000 | $0.93 | 0 | D | $1.13 · — to 2033-01-01 | 1,275,000 Common Stock | (F13) This option, which provided for vesting as to 25% of the shares on January 2, 2024 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger, in exchange for a cash payment of $1,185,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. |
| 12 | Derivative | Employee Stock Option (right to buy) | 2023-11-13 | D | D | 1,000,000 | — | 0 | D | $6.03 · — to 2028-11-30 | 1,000,000 Common Stock | (F5) This option, which provided for vesting as to 25% of the shares on December 1, 2019 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. |
| 13 | Derivative | Employee Stock Option (right to buy) | 2023-11-13 | D | D | 75,000 | — | 0 | D | $2.84 · — to 2030-06-30 | 75,000 Common Stock | (F9) This option, which provided for vesting as to 25% of the shares on July 1, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. |